Repository logo
 

Establishing population-based surveillance of diagnostic timeliness using linked cancer registry and administrative data for patients with colorectal and lung cancer.

Published version
Peer-reviewed

Loading...
Thumbnail Image

Type

Article

Change log

Authors

Pearson, Clare 
Fraser, Jess 
Peake, Michael 
Valori, Roland 
Poirier, Veronique 

Abstract

BACKGROUND: Diagnostic timeliness in cancer patients is important for clinical outcomes and patient satisfaction but, to-date, continuous monitoring of diagnostic intervals in nationwide incident cohorts has been impossible in England. METHODS: We developed a new methodology for measuring the secondary care diagnostic interval (SCDI - first relevant secondary care contact to diagnosis) using linked cancer registration and healthcare utilisation data. Using this method, we subsequently examined diagnostic timeliness in colorectal and lung cancer patients (2014-15) by socio-demographic characteristics, diagnostic route and stage at diagnosis. RESULTS: The approach assigned SCDIs to 94.4% of all incident colorectal cancer cases [median length (90th centile) of 25 (104) days] and 95.3% of lung cancer cases [36 (144) days]. Advanced stage patients had shorter intervals (median, colorectal: stage 1 vs 4 - 34 vs 19 days; lung stage 1&2 vs 3B&4 - 70 vs 27 days). Routinely referred patients had the longest (colorectal: 61, lung: 69 days) and emergency presenters the shortest intervals (colorectal: 3, lung: 14 days). Comorbidities and additional diagnostic tests were also associated with longer intervals. CONCLUSION: This new method can enable repeatable nationwide measurement of cancer diagnostic timeliness in England and identifies actionable variation to inform early diagnosis interventions and target future research.

Description

Keywords

Colorectal cancer, Diagnostic intervals, Early detection of cancer, Early diagnosis, England, Lung cancer, Population-based cancer registries, Secondary care

Journal Title

Cancer Epidemiology

Conference Name

Journal ISSN

1877-7821
1877-783X

Volume Title

61

Publisher

Elsevier
Sponsorship
GL is supported by a Cancer Research UK Advanced Clinician Scientist Fellowship (award C18081/A18180). GL is an associate director (co-investigator) of the multi-institutional CanTest Research Collaborative funded by a Cancer Research UK Population Research Catalyst award (C8640/A23385)